Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packagi…
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packagi…
ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (…
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances i…
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exc…
. - Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus op…
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development…
Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms Roun…